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Available online 23 November 2018Background:Macrolides are commonly prescribed for respiratory infections and asthma-like episodes in children.
While their clinical beneﬁts have been proved, concerns regarding the side-effects of their therapeutic use have
been raised. Here we assess the short- and long-term impacts of azithromycin on the gut microbiota of young
children.
Methods:We performed a randomized, double-blind, placebo-controlled trial in a group of children aged 12–-
36 months, diagnosed with recurrent asthma-like symptoms from the COPSAC2010 cohort. Each acute asthma-
like episode was randomized to a 3-day course of azithromycin oral solution of 10 mg/kg per day or placebo.
Azithromycin reduced episode duration by half, which was the primary end-point and reported previously.
The assessment of gut microbiota after treatment was the secondary end-point and reported in this study.
Fecal samples were collected 14 days after randomization (N= 59, short-term) and again at age 4 years (N=
49, long-term, of whomN=18were placebo treated) and investigated by 16S rRNA gene amplicon sequencing.
Findings: Short-term, azithromycin caused a 23% reduction in observed richness and 13% reduction in Shannon
diversity. Microbiota composition was shifted primarily in the Actinobacteria phylum, especially a reduction of
abundance in the genus Biﬁdobacterium. Long-term (13–39months after treatment), we did not observe any dif-
ferences between the azithromycin and placebo recipients in their gut microbiota composition.
Interpretation:Azithromycin treatment induced a perturbation in the gutmicrobiota 14 days after randomization
but did not have long-lasting effects on the gut microbiota composition. However, it should be noted that our
analyses included a limited number of fecal samples for the placebo treated group at age 4 years.
Fund: Lundbeck Foundation, Danish Ministry of Health, Danish Council for Strategic Research, Capital Region Re-
search Foundation, China Scholarship Council.








There has been a rapid rise in the use of antibiotics over the past de-
cades [1]. Respiratory infections account for the majority of hospital
visits during which antibiotics are prescribed [2]. Even though current
guidelines do not recommend antibiotics for the treatment of asthma-
like episodes in young children [3], they are among themost commonly
prescribed drugs for this condition [4]. Macrolides are often prescribed
to children in USA [5], especially to those with respiratory infectionsiology, Department of Biology,
K 2100 Copenhagen, Denmark.
. This is an open access article underand penicillin allergies [6–9]. They are considered safe, well-tolerated
and possess antimicrobial activity against gram-positive cocci, such
as Streptococcus pneumoniae, and gram-negative cocci Moraxella
catarrhalis and atypical pathogens such as Mycoplasma pneumoniae
[7]. Besides these activities, azithromycin, a second-generation
macrolide, shows antimicrobial activity against microorganisms that
erythromycin has no or marginal effect on such as Haemophilus
inﬂuenzae [10]. We recently reported a reduction in the duration of
asthma-like symptoms by half after azithromycin treatment [11]. How-
ever, the use of antibiotics for reducing such episodes in children does
raise concerns given theworldwide action plans to reduce per capita an-
tibiotic consumption. On the one hand, it has been well documented
that antibiotic consumption is the primary driver of antibiotic resistancethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Findings from our previous studies showed that antibiotics such
as azithromycin could shorten the duration of asthma-like symp-
toms in young children. While the clinical benefits of azithromycin
intervention have been proved, the potential drawbacks of its use
still remain. Considering the associations of gut microbiota with
health problems, it is important to investigate the potential conse-
quences introduced to the gut microbiota when azithromycin is
prescribed in clinic. On Feb 4, 2018,we searched the scientific lit-
erature in PubMed (with no date or language restrictions) for the
various combinations of the following search terms “antibiotics”,
“RCT”, “intestinal”, and “gut”. We identified all previous studies re-
garding the influence of antibiotics on the gut microbiota in chil-
dren. Only few publications were double-blind, randomized,
placebo-controlled trial (DB-RCT) design, among which none had
investigated the long-term effect of antibiotic administration on
gut microbiota.
Added value of this study
This study, to our knowledge, is the first DB-RCT investigating
both short- and long-term impacts of azithromycin treatment on
the gut microbiota composition in children. These data showed a
massive perturbation of gut microbiota composition shortly after
azithromycin treatment, but the long-lasting adverse effects re-
garding such perturbationswere not observed. However, our anal-
yses did have a limited number of fecal samples for the placebo
treated group at age 4 years.
Implications of all the available evidence
Even though our previous study proved the clinical benefits of
azithromycin treatment, current guidelines do not recommend an-
tibiotics for the treatment of asthma-like episodes in young chil-
dren. Compared to the clearly observed disturbance of the gut
microbiota composition shortly after azithromycin treatment, its
long-term effects regarding such disturbance were not detected.
These findings suggested that antibiotic intervention is a strong
factor in influencing the gutmicrobiota for short-term, but the gen-
eral concerns regarding the undesired, long-lasting impact are alle-
viated. However, for long-term effects, we were able to analyze
only a limited number of fecal samples for the placebo treated
group (N = 18) at age 4 years. Nevertheless, the impact of
azithromycin treatment at the gene level, such as the gut
resistome, and the correlations of such treatment with health
problems later in life need to be investigated.
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other hand, the treatment of recurrent asthma-like episodes in children
represents a major unmet clinical need that has an impact on both the
children's quality of life and healthcare resources. Naturally, the beneﬁts
and potential drawbacks of antibiotic use for acute management of
asthma-like episodes represent a clinical dilemma.Whilst azithromycin
is efﬁcient at reducing episodes duration in young children with recur-
rent asthma-like symptoms, its potential long-term impact on the de-
velopment of gut microbiota needs to be addressed.
The gut microbiota of adults is a complex and relatively stable com-
munity, involved in both host metabolic activity [15] and immune func-
tion [16]. However, the taxonomic composition and the structure of this
community is highly variable during the ﬁrst 2–3 years of life [17] and iscontinuously inﬂuenced by numerous factors [18–20], of which antibi-
otic use is suggested to have the most profound effects [21]. Trasande
et al. [22] found that the earlier in life an antibiotic is prescribed, the
greater its inﬂuence on bodymass index (BMI). Studies have previously
shown that the gut microbiota is important during the ﬁrst year of life,
as reduced diversity was associated with increased risk of allergic dis-
ease [23–25] and delayed maturation can trigger an inherited asthma
risk [26]. Alterations of the gut microbiota during this critical window
have been suspected to have long-lasting consequences [27], such as
decreased richness of the gut microbiota [28]. Although the bacterial
richness can recover rapidly in adults [29], high level of antibiotic resis-
tance genes are still observed years later [30,31]. Furthermore, antibi-
otics can potentially induce the enrichment of antibiotic resistant
strains [32], pathogen invasion facilitated by perturbation of non-
target commensal gut microbes [33], and community-wide alterations
in the gut microbiota composition [34].
Recently, two double-blind, randomized, placebo-controlled trials
(DB-RCTs) have investigated the short-term impact of azithromycin
treatment on the gut microbiota in children. Both studies found a de-
crease in richness and diversity of the gutmicrobiota and an altered tax-
onomic composition [35,36]. In contrast to the short-term impact of
azithromycin on the gut microbiota in children, its long-term effects
are not well known. One observational study suggested inﬂuences on
children's gut microbiota for up to 2 years after macrolide treatment
(s) [34]. We therefore explored these effects in a nested DB-RCT in the
unselected Copenhagen Prospective Studies on Asthma in Childhood
2010 (COPSAC2010) mother-child cohort [37]. Here, we investigate
both short-term and long-term impact of azithromycin treatment on
the gut microbiota in children. Our study aims to clarify concerns re-
garding the disturbance of gut microbiota composition when using
azithromycin for acute management of recurrent asthma-like episodes
in young children.
2. Materials and methods
2.1. Study design and participants
As part of the COPSAC2010 cohort, the parents ﬁlled out a structured
symptoms diary of their children's airway symptoms every day from
birth. Parents of children, aged 12–36 months, were invited to partici-
pate in the DB-RCT if diagnosed with recurrent asthma-like symptoms,
deﬁned as: ﬁve episodes of troublesome lung symptoms within
6 months; 4 weeks of continuous symptoms; a severe acute episode
needing oral prednisolone or hospital admission. Exclusion criteria
were macrolide allergy, heart, liver, neurological, kidney disease and
or one or more clinical signs of pneumonia. More details regarding co-
hort enrollment can be found in our previous publication [11].
Children participating in the DB-RCTwere prescribed a 3-day course
of oral azithromycin solution of 10 mg/kg per day or matching placebo
at acute asthma-like episodes from 12 to 36 months and fecal samples
were collected 14 days after randomization and no baseline samples
were collected before treatment (Fig. 1a). Children could be included
in the trial at a maximum of seven asthma-like episodes, with each
treatment randomized independently of any prior treatments. Because
participations of children in the DB-RCT were episode driven, children
would be invited to participate again if they experienced later episodes.
Therefore, additional participations in the trial occurred after a random
time interval. Fecal sample was collected from each child when they
were 4 years old in the same manner [26].
2.2. Study population
In the DB-RCTs, a total of 72 children (mean age 2·0 years [SD 0·6])
were recruited, each with one to seven episodes (Fig. 1). A total of 124
fecal samples from 62 children were received. After removing eight
samples due to low sample quality, the remaining 116 samples from
a b 
Fig. 1. (a) Trial proﬁle showing the study design of the ﬁrst participation speciﬁcally and all possible following participations. Dashed lines refer to possible sources a sample was from.
(b) Barplot showing the distribution of treatments at the ﬁrst to sixth participation in the DB-RCTs and at 4 years. AZT at 4 years corresponds to children with at least a single
azithromycin treatment, whereas placebo are the children who did not receive any azithromycin treatments.
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Since some children participated in the DB-RCT more than once, to
avoid within-child correlation, only samples collected at the ﬁrst partic-
ipation were used for short-term analysis and were grouped based on
how children were treated (azithromycin or placebo) (Fig. 1b).
Among these 59 children, at their ﬁrst participation, 29 were from the
azithromycin-treated (AZT) group and 30 were from the placebo
group. The baseline characteristics of recruited children in the DB-RCT
are shown in Supplementary Table 1 and none of the clinical covariates
differed signiﬁcantly between treatment groups.
At 4 years of age, fecal samples were collected from 49 children; of
which 31 samples were from children who were treated with
azithromycin at least once during the DB-RCTs and the remaining 18
samples were from children who only received placebo (Fig. 1b).
2.3. Randomization and masking
Each asthma-like episodewas randomized to either azithromycin or
placebo. Treatments were randomly allocated at the Pharmacy of
Glostrup (Copenhagen, Denmark) with the computer generated ran-
dom numbers in blocks of ten. The copies of randomized code were
kept at the research site and the pharmacy in sealed envelopes. Investi-
gators and participating families were masked to treatment assignment
until children turned 3 years old. Those assessing primary outcome
were masked; those doing secondary outcome, which is presented in
this study, were not.
2.4. DNA extraction, sequencing, and bioinformatic analysis
DNA extraction and sequencing were performed as described by
Mortensen et al. [38] Brieﬂy, the microbial DNA was extracted usingthe PowerMag® Soil DNA Isolation Kit on the EpMotion®automated pi-
petting system, EpMotion 5075 (Eppendorf). Themicrobiota was inves-
tigated by 16S rRNA gene sequencing using a two-step PCR procedure
targeting the V4 region (~290 bp; primers 515F [5′-GTGCCAGCMGCCG
CGGTAA-3′] and 806R [5′-GGACTACHVGGGTWTCTAAT-3′]). Paired-
end sequencing (2× 250 bp)was performed on the IlluminaMiSeq Sys-
tem (Illumina Inc., CA, USA) with the MiSeq Reagent Kits v2 (Illumina
Inc., CA, USA); 5·0% PhiX was included as an internal control.
Bioinformatic analysis was performed as described by Stokholm
et al. [26] Brieﬂy, the raw IlluminaMiSeq sequencing outputwas primer
trimmed (biopieces), quality ﬁltered and merged (UPARSE), and de-
novo operational taxonomic unit (OTU) clustered at 97% (vsearch). A
phylogenetic tree was built (QIIME) and the taxonomy was predicted
against the Greengenes database (version of 2013).
We used rarefaction curves to determine the minimum sequencing
depth necessary to describe themicrobiota of each sample (Supplemen-
tary Fig. 1). The rarefaction curves showed that Shannon diversity
reaches asymptotes for samples at 1000 sequences. Based on this, sam-
ples with less than 2000 sequences were excluded.
2.5. Statistical analysis
Continuous and categorical data of baseline characteristics were an-
alyzed with t-test and chi-square test respectively. The sample size of
this study was estimated based on the primary end-point (episode du-
ration) and has been reported previously [11].
The effect of azithromycin on alpha diversity (Shannon index and
observed richness) was assessed with two linear regression models
(function “lm” in R-package “stats”): one for short-term effect of
azithromycin treatment (14 days after randomization, at theﬁrst partic-
ipation), age of a child was included as a covariate; one for long-term
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RCT was included as a covariate. To fulﬁll the assumptions of linear re-
gression, Shannon index at 4 years of age was transformed with
“boxcox” in R-package “MASS” because of the violation of normality.
For beta diversity, comparisons of UniFrac distances (R-package
“phyloseq”) between groups were tested with Permutational Multivar-
iate Analysis of Variance with adonis (R-package “vegan”) (treatment
and age were included as variables) [39,40]. Comparisons of relative
abundance of taxa at all phylogenetic levels between treatment groups
were assessed with permutation test [41].
To identify genera that were most correlated with treatment, a Ran-
dom Forest model (named as “RF-1”) was performed at genus level (R-
package “randomForest”) [42]. Its performance was validated via
20 cycles of 10-fold cross-validation (200 iterations in total), with
5000 trees per iteration. The parameter “mtry” was tuned by 10 cycles
of 10-fold cross-validation (100 iterations in total) of all possible values.
To assess the recovery of gut microbiota, we built two Random For-
estmodels at OTU level based on fecal samples collected at the ﬁrst par-
ticipation (RF-2 model) and 4 years of age (RF-3 model). These two
modelswere performedwith5000 trees and thedefault value of param-
eter “mtry”. The prediction accuracy of Random Forest models was ob-
tained from the confusion matrix and Area Under the ROC Curve (AUC)
was calculated.
2.6. Governance
The COPSAC2010 study was approved by the Local Ethics Committee
for Copenhagen (H-B-2008-093) and the Danish Data Protection
Agency (2015–41–3696). This DB-RCT was approved separately by;
the Local Ethics Committee (H-3-2010-065), theDanishData Protection
Agency (2010–41–5023), the Danish Health and Medicines AuthorityObserved richness












Fig. 2. Short-term effect: Alpha diversity over age between groups. Distribution of observed rich
line indicates the linear regression of the correlation between age and alpha diversity.(2612–4329), and registered at ClinicalTrials.gov (NCT01233297). Par-
ents of children gave written and oral informed consent before enrol-
ment of participants. The complete COPSAC biobank is publicly
available at the Danish National Biobank (www.biobankdenmark.dk).
The entire COPSAC data, including the DB-RCT speciﬁc data, are cur-
rently being transferred to a publicly available database (the Danish
Data Archive, www.sa.dk).
3. Results
3.1. Short-term: alteration of alpha and beta diversity at day 14
At day 14, after randomization, 30 AZT children had signiﬁcantly
lower richness in the fecal samples compared to the 29 placebo children
(177·8 ± 56·0 [mean± standard deviation] vs. 230·6 ± 61·2, respec-
tively, p = 0·0006; Fig. 2). Similarly, Shannon diversity was signiﬁ-
cantly lower in the AZT group compared to the placebo group (2·96
± 0·80 [mean ± standard deviation] vs. 3·41 ± 0·58, respectively,
p = 0·009). Both alpha diversity indices increased over age, during
which the discrepancies in diversity between groups reduced.
Based on UniFrac distance, the principal coordinates analysis (PCoA)
plot illustrated that the AZT group partially overlappedwith the placebo
group; treatment accounted for a small but signiﬁcant proportion of
variance (R2 = 3·8%, p=0·027 and R2 = 4·2%, p=0·0007, weighted
and un-weighted distance, respectively; Supplementary Fig. 2).
3.2. Short-term: alteration of taxonomic composition at day 14
Bacteroidetes and Firmicuteswere themost abundant phyla (relative
abundance 57·2% and 31·6%, respectively), followed by Proteobacteria,
Actinobacteria, and Verrucomicrobia; these ﬁve phyla had a combinedShannon diversity
1·0 1·5 2·0 2·5 3·0
ears)
T Placebo
ness and Shannon diversity for the AZT (red lines) and the placebo (blue lines) groups. The
269S. Wei et al. / EBioMedicine 38 (2018) 265–272relative abundance of 99·7%. We observed a decrease in the relative
abundance of Actinobacteria in the AZT group compared to the placebo
group (Supplementary Table 2). Notably, Biﬁdobacterium accounted
for the majority of composition changes in Actinobacteria, which was
evident at all taxonomic ranks, particularly OTU level, where 17 of 21
signiﬁcant OTUs belonged to Biﬁdobacterium and all were dramatically
reduced in the AZT group.
3.3. Short-term: random forest models based on taxonomic composition at
day 14
To further elucidate the impact of azithromycin treatment on the gut
microbiota composition and to identify its recovery purely based on the
gut microbiota, we built two Random Forest models, a supervised
machine-learning algorithm, based on the 59 samples collected at the
ﬁrst participation. The ﬁrst model (RF-1), built at genus level, produced
an AUC of 0·89 (p=0, by permutation test with 10,000 iterations), and
was used to identify genera that were most affected by azithromycin
treatment. The genera having best treatment-discriminatory perfor-
mance were identiﬁed based on importance scores (Fig. 3), among
which Biﬁdobacterium showed an exceedingly higher score than the re-
maining genera. The second model (RF-2), built at OTU level, produced
an AUC of 0·92 (p=0, by permutation test with 10,000 iterations), and
was used to assess the recovery of gut microbiota at the second partici-
pation and 4 years of age.Fig. 3. Short-term effect: The top 20 taxa with the highest importance score (Gini index) by th
relative abundances.3.4. Second participation: partial recovery of gut microbiota
After the ﬁrst randomization, 28 children fulﬁlled the inclusion
criteria again and participated in the DB-RCT for their second time
and also had a fecal sample collected. Although the time intervals be-
tween two participations were variable (mean 223·3 days [SD
152·8]), the relatively longer time than 14 days enabled us to assess
the recovery of gut microbiota after azithromycin treatment; 11 of
these 28 children were treated with placebo at their second random-
ization, and the effect of their ﬁrst treatment could be evaluated here.
Among these 11 children, six were treated with azithromycin, and
ﬁve were treated with placebo at their ﬁrst randomization. No differ-
ence between groups was observed in either alpha diversity (median
of observed richness, 183 ± 74·5 vs. 233 ± 64·0 for AZT and pla-
cebo, respectively, p = 0·052, Wilcoxon rank-sum test; median of
Shannon, 3·43 ± 0·89 vs. 3·94 ± 0·47 for AZT and placebo, respec-
tively, p = 0·13, Wilcoxon rank-sum test) or beta diversity
(weighted Unifrac, R2 = 12·8%, p = 0·22). Next, we applied RF-2
model to assess the recovery of gut microbiota and we
correctly identiﬁed the treatments for three of six samples in
azithromycin-treated group and ﬁve of ﬁve samples in placebo
group (AUC = 0·94, p = 0, by permutation test with 10,000 itera-
tions). The prediction with Random Forest model indicated that half
of the children who were treated with azithromycin at their ﬁrst par-
















Fig. 4. Long-term effect: Alpha and beta diversity between groups. (a) Dotplot showing the distribution of observed richness and Shannon diversity for the AZT (red) and placebo (blue)
groups. Black dots indicate the mean; error bars indicate the standard deviation. (b) Weighted UniFrac distances between AZT (red) and placebo (blue) groups, visualized by principal
coordinates analysis (PCoA), with ellipses encircling 75% of samples from each group.
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To assess the long-term impact of azithromycin, we investigated the
49 fecal samples collected from AZT (N = 31) and placebo (N = 18)
groups when children were 4 years old. We did not observe any signif-
icant differences in alpha diversity (mean of observed richness, 181·5
± 49·9 vs. 188·9 ± 41·2 for AZT and placebo, respectively, p= 0·66;
mean of Shannon, 3·47±0·72 vs. 3·64±0·44 for AZT and placebo, re-
spectively, p = 0·90; Fig. 4a) or beta diversity between groups
(weighted Unifrac, R2 = 2·0%, p = 0·37; Fig. 4b). Furthermore, we
did not observe any OTUs differ signiﬁcantly in relative abundance be-
tween groups. Next, the RF-2 model was applied to assess the recovery
of these children based on the gut microbiota. Of the 31 children in AZT
group, 26 were identiﬁed as placebo, resulting in an AUC of 0·69 (p=
0·013, by permutation test with 10,000 iterations). To further validate
the result, we built a third Random Forest model for 4-year samples at
the OTU level (RF-3 model) to differentiate the treatment groups. The
RF-3 model produced an AUC of 0·56 (p = 0·24, by permutation test
with 10,000 iterations).4. Discussion
Azithromycin had a strong effect on the composition of gutmicrobi-
ota 14 days post-treatment, but these effects did not persist to 4 years of
age (13–39 months after the last treatment) in our DB-RCT of
azithromycin in young children [11]. Current guidelines discourage
the use of antibiotics during asthma-like episodes in early life due to
lack of evidence of severe bacterial infections as main episode triggers
[3], and adverse effects on the colonizing microbiota [43,44]. Recentevidence showed that bacteria are important triggers for asthmatic ep-
isodes [45], and that azithromycin reduced theduration of symptomsby
half [11].
In the present study, the 3-day course of azithromycin resulted in a
perturbation of the gut microbiota 14 days after randomization. Alpha
diversity was signiﬁcantly reduced and the microbiota composition
was shifted. However, long-lasting impact of azithromycin on the gut
microbiota composition was not observed.
In our study, 14 days after randomization, children in the AZT group
had 23% lower richness and 13% lower Shannon diversity in their fecal
samples compared to the placebo group. In particular, the relative abun-
dance of Actinobacteriawas reduced. Based on the taxonomic composi-
tion, the Random Forest model identiﬁed study arms with high
accuracy, the genus Biﬁdobacterium was the most important
contributor.
We observed increasing richness and Shannon diversity with age
of the child, which represented an ongoing maturation of the gut mi-
crobiota. Of interest, the later the azithromycin prescribed to chil-
dren, the smaller the difference in alpha diversity seemed between
two treatment groups. This decreasing discrepancy may be attributed
to early antibiotic administration having stronger microbiota
perturbing effects in younger children where the microbiota is still
developing [22] compared to the older children, who may recover
faster because of a more mature baseline composition. However,
this study did not provide sufﬁcient statistical power to conﬁrm a
signiﬁcant interaction between age and treatment, therefore further
investigation is needed.
Long-term effects of azithromycin treatment were not observed. At
4 years of age (13–39months after the last treatment),we could not dis-
tinguish children according to AZT or placebo group based on alpha
271S. Wei et al. / EBioMedicine 38 (2018) 265–272diversity, beta diversity, discriminant OTUs or by Random Forest
models. The full recovery of children's gutmicrobiota in AZT group indi-
cated that azithromycin treatment did not induce long-term composi-
tional perturbations.
Our results are at odds with an observational study of children on
the inﬂuence of macrolides on gut microbiota [34]. They observed
lower richness for subjects who were exposed to macrolides within
the preceding 2 years compared to the control group. The discrepancy
may derive from some differences existing between our data and that
of Korpela et al. The recovery time (13–39 months) of our subjects is
longer compared to theirs (12–24 months); the age (median
2·0 years [IQR 1·0]) of our subjects is younger compared to theirs (me-
dian 5 years). Furthermore, observational studies may always have ad-
ditional confounding factors, which drive both antibiotic use and
microbial differences.
Biﬁdobacterium, the dominant genus in Actinobacteria, was one of
the most affected genera by azithromycin treatment and had an ex-
ceedingly high importance score determined by Random Forest
model. The relative abundance of Biﬁdobacterium in the AZT group
was 50-fold lower compared to the placebo group and in many
cases they were too low to be detected. Biﬁdobacterium has been
shown to be one of the most affected genera by clarithromycin and
metronidazole in the gut [31]. Most of the Biﬁdobacterium spp. strains
are likely susceptible to macrolides and other antibiotics [46]. Similar
results were observed in Korpela's study where the abundance of
Biﬁdobacterium was reduced around 4-fold when a participant was
treated with macrolides during the preceding 6 months. However,
two recent DB-RCTs found no difference in Biﬁdobacterium abundance
between groups [35,36]. These discrepancies may derive from the dif-
ferent characteristics of study population, since Parker's and Doan's
populations were from south India and Niger, respectively, compared
to our cohort from Denmark.
Our results revealed that azithromycin treatment for asthma-like
symptoms in childhood led to a transient perturbation of the gut
microbiota composition (N = 59, 12–36 months of age); however,
long-term impact of azithromycin regarding such perturbations
was not observed (N = 49, 4 years of age). Our study may alleviate
concerns about adverse effects of azithromycin use in young chil-
dren. Furthermore, considering the strength of DB-RCT and
azithromycin likely being the main source of disturbance on gut mi-
crobiota, we speculate that our ﬁndings may also extend to non-
asthmatic children (12 to 36 months of age) who have been pre-
scribed azithromycin.
However, limitations should also be acknowledged. The children
may have received antibiotics for other reasons during these ﬁrst
4 years of life, but that would work against the null hypothesis. Even
though we had 116 samples from the 12–36 months period, in order
to avoid within-child correlations, only 59 samples from the ﬁrst ran-
domization were used for short-term analysis. Therefore, we may
have low statistical power to distinguish the differences between treat-
ment groups. A similar issue for the 4-year samples was that most chil-
dren had been randomized to azithromycin at one point during the trial
period, reducing the size of the placebo group compared to the AZT
group. In addition, exclusions and loss to follow up also resulted in the
reduction of sample size. Furthermore, since we did not collect baseline
samples before randomization, we could only assess the alteration of
gutmicrobiota at the group level instead of tracking individual child be-
fore and after treatment. For the recovery assessment of the gut micro-
biota at the second participation, we were limited by both a small
sample size and variable time intervals between participations. Another
limitation was the resolution of 16S rRNA gene sequencing techniques
and perturbation caused by azithromycin at the gene level, such as an-
timicrobial resistance, could not be evaluated. Most OTUs were classi-
ﬁed to genus level, but for some OTUs the resolution was insufﬁcient
for such classiﬁcation, therefore the unclassiﬁed taxa might introduce
bias for statistical analysis.Acknowledgments
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